No­var­tis to make com­mer­cial Carvyk­ti; Re­ci­pharm di­vests sev­en fa­cil­i­ties; Lil­ly’s Zep­bound in short­age 

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial up­dates on new builds, col­lab­o­ra­tions, re­calls and more.

No­var­tis ex­tend­ed its deal with John­son & John­son and Leg­end Biotech to com­mer­cial­ly man­u­fac­ture Carvyk­ti, ac­cord­ing to a March 29 SEC fil­ing. No­var­tis will make the CAR-T ther­a­py at its fa­cil­i­ty in Mor­ris Plains, NJ, un­til the end of 2029. The orig­i­nal April 2023 deal saw No­var­tis make Carvyk­ti for clin­i­cal tri­als.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER